课题基金 / 基金详情

TRANSYNAPTIC CORTICAL APOPTOSIS--MECHANISMS & THERAPIES

TRANSYNAPTIC CORTICAL APOPTOSIS--MECHANISMS & THERAPIES
突触皮质细胞凋亡--机制
批准号:
6726168
负责人:
VASSILIS E. KOLIATSOS
金额:
$38.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-04-01 至 2006-03-31

项目摘要

项目成果

VASSILIS E. KOLIATSOS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Verbatim from the Applicant's Abstract) Transsynaptic degeneration of corticocortical pathways is a central mechanism for the propagation of pathology an cell death in systems degenertions involving the cerebral cortex, including Alzheimer's disease. We propose that this type of degeneration may represent an appropriate and realistic target of pathogenic events in these disorders. In the present proposal, we focus on a very reliable in vivo model of transsynaptic cortical degeneration that we have recently developed, i.e., the apoptotic death of pyramidal neurons in the piriform cortex after their disconnection from the olfactory bulb. We investigate specific cellular/molecular events subsequent to bulbotomy such as excitotoxic-type alterations of distal dendrites of deafferented neurons, NOS/No signaling impacting on these neurons; and cell cycle and death genes such as Cyclin D1 and bax. To confirm data from anatomical/expression experiments, we use a number of pharmacological interventions, including: protein synthesis inhibitors that influence apoptosis but not excitotoxicity; small molecules that target glutamate synthesis, release and binding to block excitotoxicity and, in so doing, ameliorate of abolish apoptotic cortical cell death; NOS inhibitors/NO scavengers; cyclin-dependent kinase inhibitors to block cyclin signaling; and caspase inhibitors. We also use mice with genetic advantages that prevent apoptotic neuronal death (e.g., nNOS nulls, bax nulls, ICE-dominant negative Tgs). We expect that these carefully controlled investigations will shed light on critical intermediate mechanisms of cortical degenerations and will suggest clinically advantageous methods to treat these disorders.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1097/wnr.0000000000000203
发表时间: 2014-09-10
期刊: Neuroreport
影响因子: 1.7
作者: [Rossi SL, Mahairaki V, Zhou L, Song Y, Koliatsos VE]
通讯作者: Koliatsos VE
DOI: 10.1016/j.jneumeth.2009.02.006
发表时间: 2009-05-15
期刊: Journal of neuroscience methods
影响因子: 3
作者: [Mahairaki V, Xu L, Farah MH, Hatfield G, Kizana E, Marbán E, Koliatsos VE]
通讯作者: Koliatsos VE
Estrogens modulate experimentally induced apoptosis of granule cells in the adult hippocampus.
雌激素调节实验诱导的成年海马颗粒细胞凋亡。
DOI: 10.1002/cne.1393
发表时间: 2001
期刊: The Journal of comparative neurology
影响因子: --
作者: [Liu,Z, Gastard,M, Verina,T, Bora,S, Mouton,PR, Koliatsos,VE]
通讯作者: Koliatsos,VE
Traumatic axonopathy and Alzheimer tau propagation
  • 批准号:
    10590970
  • 项目类别:
  • 资助金额:
    $45.03万
  • 财政年份:
    2023
  • 负责人:
    VASSILIS E. KOLIATSOS
  • 依托单位:
Traumatic Axonopathy in the CNS as Wallerian degeneration
  • 批准号:
    10531592
  • 项目类别:
  • 资助金额:
    $47.6万
  • 财政年份:
    2021
  • 负责人:
    VASSILIS E. KOLIATSOS
  • 依托单位:
Traumatic Axonopathy in the CNS as Wallerian degeneration
  • 批准号:
    10320956
  • 项目类别:
  • 资助金额:
    $47.6万
  • 财政年份:
    2021
  • 负责人:
    VASSILIS E. KOLIATSOS
  • 依托单位:
Sequence of physiological events during oxygen conserving reflex activation leading to sudden death in epilepsy
  • 批准号:
    10643799
  • 项目类别:
  • 资助金额:
    $40.94万
  • 财政年份:
    2020
  • 负责人:
    VASSILIS E. KOLIATSOS
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: